Pith. sign in

REVIEW 5 minor 83 references

Artificial Intelligence Across the Cardiac Amyloidosis Diagnostic Pathway: From Single-Modality Detection to Multimodal Clinical Integration

T0 review · 0 major / 5 minor · reviewed 2026-07-14 · grok-4.5

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Binary detection and AI-assisted quantification on bone scintigraphy and SPECT/CT are closest to clinical translation for cardiac amyloidosis; subtype, prognosis, and treatment-response models remain early-stage, and high discrimination alo

desk verdict Solid task-based narrative review that correctly ranks scintigraphy detection and SPECT/CT quantification as nearest to translation; useful synthesis, not a new result. read the letter →

arxiv 2607.09948 v1 pith:7NGBO4J2 submitted 2026-07-10 physics.med-ph cs.LG

Diana Shadibaeva , Rochak Dhakal , Kui Zhang , Xiaofeng Yang , Saurabh Malhotra , Weihua Zhou This is my paper · ORCID
classification physics.med-phcs.LG
keywords CardiacamyloidosismachinelearningmultimodalimagingnuclearcardiologyquantitativebiomarkersSPECT/CTATTRAL
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Cardiac amyloidosis is underdiagnosed because it looks like more common heart diseases, and correct care requires separating transthyretin from light-chain disease with multimodal evidence. This narrative review organizes AI studies by clinical task—screening, detection, quantification, prognosis, and treatment-response monitoring—rather than by imaging modality, showing that each task demands different cohorts, labels, metrics, and deployment thresholds. The evidence forms a clear maturity gradient: binary uptake detection and AI-enabled SPECT/CT tracer-burden measures sit nearest clinical use, backed by large externally validated cohorts and interpretable, outcome-linked biomarkers. Subtype-aware classification, prognostic stratification, and treatment-response monitoring stay early, limited by small cohorts, enriched retrospective designs, mixed labels, incomplete external validation, and uncertain calibration at real-world prevalence. The authors argue the field should stop adding single-modality classifiers and build multimodal, subtype-aware, longitudinally validated systems that support—not replace—established diagnostic pathways.

What carries the argument

Task-based synthesis of the literature (screening, detection, quantification, prognosis, treatment-response monitoring). Grouping by clinical job rather than input modality shows why outwardly similar AI models need different cohorts, reference standards, evaluation metrics, and implementation thresholds, and why maturity differs by task.

What would settle it

A large prospective multicenter study that either (a) shows subtype-aware or treatment-response AI matching scintigraphy detection on external validation, calibration at realistic prevalence, and change in referral or outcomes, or (b) shows AI SPECT/CT quantification failing to improve management decisions or outcome linkage when deployed against established staging and biomarkers.

Watch

Extended reading notes

Core claim

Across AI applications in cardiac amyloidosis, a maturity gradient exists: binary detection of abnormal cardiac uptake and AI-assisted quantification of myocardial tracer burden on bone scintigraphy and SPECT/CT are closest to clinical translation, while subtype-aware classification, prognostic risk models, and treatment-response monitoring remain early-stage. High discrimination scores alone do not establish clinical usefulness; models must hold against relevant mimics, across subgroups, with independent reference standards, and improve real referral or management decisions inside existing workflows.

Load-bearing premise

The authors’ narrative, non-systematic selection of studies and qualitative ranking of which tasks are “closest to translation” versus “early-stage” accurately reflect the true state of the field.

Editorial extensions

If this is right

  • Scintigraphy uptake-detection models and SPECT/CT burden biomarkers (TBR, volume of involvement, cardiac pyrophosphate activity) should be prioritized for prospective workflow trials and regulatory planning first.
  • Screening and detection claims must report PPV, calibration, and performance against realistic mimics (HFpEF, hypertensive LVH, HCM, aortic stenosis), not only AUC on case-control cohorts.
  • Subtype, prognosis, and monitoring models need larger subtype-confirmed, outcome-linked, multicenter datasets before they can guide therapy choice or trial endpoints.
  • Staged multimodal pipelines (for example ECG then echo) and direct multimodal fusion should be compared head-to-head for yield, false positives, and time to diagnosis.
  • Future systems must be designed to support existing non-biopsy ATTR algorithms and monoclonal-protein testing, not replace them.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • If SPECT/CT quantification becomes a de facto monitoring standard, trial endpoints for ATTR disease-modifying drugs may shift from biomarkers and functional class toward volumetric tracer-burden change.
  • The same task-based maturity filter could be reused for other rare infiltrative or phenotypically overlapping cardiomyopathies where single-modality AUC papers currently outpace multimodal validation.
  • Equity gaps already visible in AI-ECG subgroup performance (for example ethnicity, LVH, conduction disease) will likely reappear in any deployed screening program unless post-deployment monitoring is required from day one.
  • Opportunistic CT and pre-TAVI AI case-finding may become the practical bridge that brings nuclear quantification into earlier care pathways before dedicated amyloid imaging is ordered.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

0 major / 5 minor

Summary. This narrative review synthesizes machine-learning and deep-learning applications in cardiac amyloidosis by clinical task (screening, detection, quantification, prognosis, treatment-response monitoring) rather than by input modality. It argues that binary detection of abnormal cardiac uptake on bone scintigraphy and AI-assisted SPECT/CT quantification of myocardial tracer burden are closest to clinical translation, supported by large externally validated cohorts and interpretable, outcome-linked biomarkers (TBR, VOI, CPA), whereas subtype-aware ATTR-versus-AL classification, prognostic stratification, and treatment-response monitoring remain early-stage because of small cohorts, enriched retrospective designs, heterogeneous labels, incomplete external validation, and uncertain calibration at realistic prevalence. High discrimination alone is judged insufficient; clinically useful AI must perform against relevant mimics, avoid circular reference standards, and improve decisions within established multimodal pathways. The authors therefore call for multimodal, subtype-aware, longitudinally validated systems that support rather than replace current diagnostic algorithms.

Significance. If the maturity ranking holds, the review supplies a useful organizing principle for a rapidly expanding literature and a concrete translational roadmap. The task-based framing correctly explains why apparently similar models need different cohorts, labels, metrics, and thresholds, and the ranking is anchored in the strongest primary evidence (Spielvogel et al. 2024 multicenter multi-tracer scintigraphy detection; Miller et al. 2024/2026 AI-enabled SPECT/CT quantification with outcome-linked biomarkers). Explicit disclosure of the narrative design, absence of formal risk-of-bias scoring, and the detailed supplementary task tables that list cohort size, validation level, and label type for each study make the appraisal transparent and usable by both methodologists and clinicians. The work is therefore a timely synthesis that can guide dataset design, evaluation standards, and workflow integration priorities in CA AI.

minor comments (5)
  1. Methods: state the approximate search window (last date of literature search) so readers can judge currency of the synthesis.
  2. Section 4.2.1 and Supplementary Table B: Mo et al. is correctly flagged as a preprint; ensure the main text consistently labels it as emerging/preprint evidence rather than peer-reviewed validation.
  3. Figure 4 caption and Section 5.1: a brief note that latent deep-learning features can still be paired with post-hoc explanations (saliency, SHAP) would avoid implying that only nuclear biomarkers are clinically usable.
  4. Supplementary tables: a few entries (e.g., TRACE-AI, Miller 2026 longitudinal status) use cautious language about multicenter status; align main-text citations with the same caution for consistency.
  5. Minor typographical inconsistencies (spacing around hyphens in “task-based,” occasional double spaces) can be cleaned in production.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: narrative review of external primary studies; maturity gradient is not forced by self-definition or tautological re-labeling.

full rationale

This is a narrative literature review, not a first-principles derivation or model-fitting paper. Its central claim (a task-based maturity gradient: binary scintigraphy/SPECT-CT detection and AI-enabled quantification closest to translation; subtype-aware classification, prognosis, and treatment-response monitoring still early-stage) is an interpretive synthesis of independently published cohorts (e.g., Spielvogel et al. 2024 multi-center multi-tracer detection; Miller et al. 2024/2026 AI SPECT/CT TBR/VOI/CPA biomarkers). Methods explicitly state narrative (non-systematic) design without formal risk-of-bias scoring or pooled synthesis. No equations redefine outputs as inputs; no fitted parameters are re-presented as predictions; no uniqueness theorem or ansatz is imported from the authors’ own prior work to force the ranking. Competing-interest disclosure (corresponding-author consulting) and any incidental self-citation of related imaging literature are non-load-bearing. The argument remains falsifiable against the external primary literature it cites and does not reduce by construction to its own premises.

Assumptions & free parameters 0 free parameters · 4 assumptions · 0 invented entities

As a narrative synthesis the paper inherits standard clinical and imaging assumptions of the CA diagnostic pathway and does not introduce free parameters, new physical entities, or ad-hoc mathematical axioms. Load-bearing premises are domain conventions (non-biopsy ATTR diagnosis criteria, Perugini grading, need for monoclonal-protein exclusion) plus the methodological choice to rank maturity by external validation, interpretability, and outcome linkage rather than by AUC alone.

assumptions (4)
  • domain assumption Modern CA diagnosis is inherently multimodal; no single test is sufficient across all subtypes and presentations.
    Stated in §3.1 and used throughout to justify why single-modality high-AUC models cannot replace the pathway.
  • domain assumption In the absence of monoclonal protein, grade 2–3 myocardial uptake on bone-avid scintigraphy with SPECT confirmation supports non-biopsy ATTR-CA diagnosis (Gillmore et al. criteria).
    Used as the clinical reference frame for nuclear detection and quantification claims (§3.4, Table 1).
  • domain assumption High discrimination (AUC) alone is insufficient for clinical usefulness; calibration, PPV at realistic prevalence, mimic performance, and workflow impact are required.
    Central evaluative axiom of the review (Abstract, §4.1.4, §5.3, §6.3).
  • ad hoc to paper A narrative (non-systematic) synthesis without formal risk-of-bias scoring can still support a maturity ranking of the field.
    Explicit Methods choice; the maturity gradient rests on this methodological premise.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Artificial Intelligence Across the Cardiac Amyloidosis Diagnostic Pathway: From Single-Modality Detection to Multimodal Clinical Integration." pith.science (2026). https://pith.science/paper/7NGBO4J2

@misc{pith2026260709948,
  author       = {Pith},
  title        = {Pith review of: Artificial Intelligence Across the Cardiac Amyloidosis Diagnostic Pathway: From Single-Modality Detection to Multimodal Clinical Integration},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/7NGBO4J2}},
  note         = {Machine review of arXiv:2607.09948}
}
read the original abstract

Cardiac amyloidosis (CA) is increasingly recognized but remains substantially underdiagnosed, because its clinical and imaging phenotype overlaps with more common cardiomyopathies. Definitive subtype assignment and management further require integration of multimodal evidence to distinguish transthyretin from light chain disease. Machine learning and deep learning have been applied across the diagnostic and management pathway. These applications span ECG, echocardiography, and health record-based case finding, as well as CMR and nuclear interpretation, including SPECT/CT biomarker quantification, prognostic modeling, and treatment response assessment. This narrative review synthesizes these studies by clinical tasks, namely screening, detection, quantification, prognosis, and treatment response monitoring, rather than by input modality. This task-based organization clarifies why apparently similar AI models require different cohorts, reference standards, evaluation metrics, and implementation thresholds. The evidence reveals a maturity gradient. Binary detection and AI assisted quantification on bone scintigraphy and SPECT/CT are closest to clinical translation. Detection is supported by large externally validated cohorts, and quantification by interpretable, outcome linked measurement of myocardial tracer burden. By contrast, subtype aware classification, prognostic risk stratification, and treatment response monitoring remain at an early stage. These tasks are limited by small cohorts, enriched retrospective designs, heterogeneous labels, incomplete external validation, and uncertain calibration in realistic prevalence settings. Across tasks, high discrimination alone is insufficient.

Figures

Figures reproduced from arXiv: 2607.09948 by the authors.

Figure 1
Figure 1. Pathways of AL and ATTR cardiac amyloidosis. [PITH_FULL_IMAGE:figures/full_fig_p004_1.png] view at source ↗
Figure 4
Figure 4. Feature representations in cardiac amyloidosis AI by clinical interpretability. The figure summarizes how model inputs range from latent deep-learning features to radiomics, conventional clinical variables, and quantitative nuclear biomarkers. Interpretability increases as features become more directly linked to measurable disease biology and tracer burden. 5.2 Cohort design and generalizability The apparent perform… view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

83 extracted references · 67 canonical work pages

  1. [1]

    Cardiac Amyloidosis

    Bloom MW, Gorevic PD. Cardiac Amyloidosis. Annals of Internal Medicine. 2023;176:ITC33–

    2023

  2. [2]

    https://doi.org/10.7326/AITC202303210

    work page doi:10.7326/aitc202303210

  3. [3]

    Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases

    Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021;42:1554–68. https://doi.org/10.1093/eurheartj/ehab072

    work page doi:10.1093/eurheartj/ehab072 2021

  4. [4]

    Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association

    Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142:e7–22. https://doi.org/10.1161/CIR.0000000000000792

    work page doi:10.1161/cir.0000000000000792 2020

  5. [5]

    AL (Light-Chain) Cardiac Amyloidosis

    Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis. Journal of the American College of Cardiology. 2016;68:1323–41. https://doi.org/10.1016/j.jacc.2016.06.053

    work page doi:10.1016/j.jacc.2016.06.053 2016

  6. [6]

    Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States

    Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of Cardiac Amyloidosis–Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circulation: Heart Failure. 2019;12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407

    work page doi:10.1161/circheartfailure.118.005407 2019

  7. [7]

    Redefining the Epidemiology of Cardiac Amyloidosis

    Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the Epidemiology of Cardiac Amyloidosis. A Systematic Review and Meta-Analysis of Screening Studies. European Journal of Heart Failure. 2022;24:2342–51. https://doi.org/10.1002/ejhf.2532

    work page doi:10.1002/ejhf.2532 2022

  8. [8]

    Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133:2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612

    work page doi:10.1161/circulationaha.116.021612 2016

Show all 83 references
  1. [9]

    Tafamidis Treatment for Patients With Transthyretin Amyloid Cardiomyopathy

    Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients With Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2018;379:1007–16. https://doi.org/10.1056/NEJMoa1805689

    2018 doi

  2. [10]

    Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging. Circulation: Cardiov...

    2021 doi

  3. [11]

    ASNC Practice Points: 99mTechnetium- Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis [Internet]

    American Society of Nuclear Cardiology. ASNC Practice Points: 99mTechnetium- Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis [Internet]. 2022. https://www.asnc.org/wp-content/uploads/2024/05/19110-2021-ASNC-Amyloid-Practice-Points- PYP-MAY19-2022-1.pdf

    2022

  4. [12]

    99mTc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis

    Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. 99mTc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis. Radiology. 2022;306:e221082. https://doi.org/10.1148/radiol.221082

    2022 doi

  5. [13]

    Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis

    Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure. 2019;12:e006075. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075

    2019 doi

  6. [14]

    2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis

    Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. Journal of the American College of Cardiology. 2023;81:1076–126. https...

    2023 doi

  7. [15]

    Artificial Intelligence-Enabled Fully Automated Detection of Cardiac Amyloidosis Using Electrocardiograms and Echocardiograms

    Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, et al. Artificial Intelligence-Enabled Fully Automated Detection of Cardiac Amyloidosis Using Electrocardiograms and Echocardiograms. Nature Communications. 2021;12:2726. https://doi.org/10.1038/s41467-021-22877-8

    2021 doi

  8. [16]

    Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis

    Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine OF, et al. Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clinic Proceedings. 2021;96:2768–78. https://doi.org/10.1016/j.mayocp.2021.04.023

    2021 doi

  9. [17]

    Machine Learning-Derived Electrocardiographic Algorithm for the Detection of Cardiac Amyloidosis

    Schrutka L, Anner P, Agibetov A, Seirer B, Dusik F, Rettl R, et al. Machine Learning-Derived Electrocardiographic Algorithm for the Detection of Cardiac Amyloidosis. Heart. 2021;108:1137–

    2021

  10. [18]

    https://doi.org/10.1136/heartjnl-2021-319846

    2021 doi

  11. [19]

    High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning

    Duffy G, Cheng PP, Yuan N, He B, Kwan AC, Shun-Shin MJ, et al. High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology. 2022;7:386–95. https://doi.org/10.1001/jamacardio.2021.6059

    2022 doi

  12. [20]

    International Validation of Echocardiographic Artificial Intelligence Amyloid Detection Algorithm

    Duffy G, Oikonomou EK, Easton N, Usuku H, Patel J, Katsumata Y, et al. International Validation of Echocardiographic Artificial Intelligence Amyloid Detection Algorithm. JACC: Advances. 2025;4:102067. https://doi.org/10.1016/j.jacadv.2025.102067

    2025 doi

  13. [21]

    Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence

    Ioannou A, Khouri MG, Kitai T, Vemulapalli S, Hung C-L, Lim SC, et al. Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence. Circ: Cardiovascular Imaging [Internet]. 2026 [cited 2026 July 3];19. https://doi.org/10.1161/CIRCIMAGING.125.018991

    2026 doi

  14. [22]

    Advances in Echocardiography for Cardiac Amyloidosis and Restrictive Cardiomyopathies

    Kafil TS, Canova TJ, Wang TKM, Klein AL. Advances in Echocardiography for Cardiac Amyloidosis and Restrictive Cardiomyopathies. Current Opinion in Cardiology. 2025;41:50–9. https://doi.org/10.1097/HCO.0000000000001263

    2025 doi

  15. [23]

    The Current Status of Quantitative SPECT/CT in the Assessment of Transthyretin Cardiac Amyloidosis

    Ramsay SC, Cuscaden C. The Current Status of Quantitative SPECT/CT in the Assessment of Transthyretin Cardiac Amyloidosis. Journal of Nuclear Cardiology. 2019;27:1464–8. https://doi.org/10.1007/s12350-019-01935-1

    2019 doi

  16. [24]

    Postdevelopment Performance and Validation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis

    Harmon DM, Mangold K, Baez Suarez A, Scott CG, Murphree DH, Malik A, et al. Postdevelopment Performance and Validation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis. JACC: Advances. 2023;2:100612. https://doi.org/10.1016/j.jacad...

    2023 doi

  17. [25]

    Deep Learning to Classify AL Versus ATTR Cardiac Amyloidosis MR Images

    Germain P, Vardazaryan A, Labani A, Padoy N, Roy C, El Ghannudi S. Deep Learning to Classify AL Versus ATTR Cardiac Amyloidosis MR Images. Biomedicines. 2023;11:193. https://doi.org/10.3390/biomedicines11010193

    2023 doi

  18. [26]

    Leveraging a Vision Transformer Model to Improve Diagnostic Accuracy of Cardiac Amyloidosis With Cardiac Magnetic Resonance

    Cockrum J, Nakashima M, Ammoury C, Rizkallah D, Mauch J, Lopez D, et al. Leveraging a Vision Transformer Model to Improve Diagnostic Accuracy of Cardiac Amyloidosis With Cardiac Magnetic Resonance. JACC: Cardiovascular Imaging. 2024;18:278–90. https://doi.org/10.1016/j.jcmg.20...

    2024 doi

  19. [27]

    Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study

    Weberling LD, Ochs A, Benovoy M, Aus Dem Siepen F, Salatzki J, Giannitsis E, et al. Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study. Circ: Cardiovascular Imaging [I...

    2025 doi

  20. [28]

    A Robust Radiomic-Based Machine Learning Approach to Detect Cardiac Amyloidosis Using Cardiac Computed Tomography

    Lo Iacono F, Maragna R, Pontone G, Corino VDA. A Robust Radiomic-Based Machine Learning Approach to Detect Cardiac Amyloidosis Using Cardiac Computed Tomography. Frontiers in Radiology. 2023;3:1193046. https://doi.org/10.3389/fradi.2023.1193046

    2023 doi

  21. [29]

    Deep Learning on Bone Scintigraphy to Detect Abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis

    Delbarre M, Girardon F, Roquette L, Blanc-Durand P, Hubaut M, Hachulla E, et al. Deep Learning on Bone Scintigraphy to Detect Abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. JACC: Cardiovascular Imaging. 2023;16:1085–95. https://doi.org/10.1016/j.jcmg.2023.01.014

    2023 doi

  22. [30]

    Spielvogel CP, Haberl D, Mascherbauer K, Ning J, Kluge K, Traub-Weidinger T, et al. Diagnosis and Prognosis of Abnormal Cardiac Scintigraphy Uptake Suggestive of Cardiac Amyloidosis Using Artificial Intelligence: A Retrospective, International, Multicentre, Cross- Tracer Devel...

    2024 doi

  23. [31]

    Bhattaru A, Rojulpote C, Vidula M, Duda J, Maclean MT, Swago S, et al. Deep Learning Approach for Automated Segmentation of Myocardium Using Bone Scintigraphy Single-Photon Emission Computed Tomography/Computed Tomography in Patients With Suspected Cardiac Amyloidosis. Journal...

    2024 doi

  24. [32]

    Deep Learning–Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis

    Miller RJH, Shanbhag A, Michalowska AM, Kavanagh P, Liang JX, Builoff V, et al. Deep Learning–Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis. Journal of Nuclear Medicine. 2024;65:1144–50. https://doi.org/10.2967/jnumed.124.267542

    2024 doi

  25. [33]

    Impact of Disease-Modifying Therapy on [99mTc]Tc-DPD SPECT/CT Markers in Transthyretin Cardiac Amyloidosis Enabled by Artificial Intelligence

    Spielvogel CP, Köfler M, Jiang Z, Ning J, Yu J, Haberl D, et al. Impact of Disease-Modifying Therapy on [99mTc]Tc-DPD SPECT/CT Markers in Transthyretin Cardiac Amyloidosis Enabled by Artificial Intelligence. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53:3...

    2025 doi

  26. [34]

    Multimodal Fusion of Echocardiography and Electronic Health Records for the Detection of Cardiac Amyloidosis

    Feng Z, Sivak JA, Krishnamurthy AK. Multimodal Fusion of Echocardiography and Electronic Health Records for the Detection of Cardiac Amyloidosis. 2024. https://doi.org/10.48550/arXiv.2404.11058

    2024 doi arXiv

  27. [35]

    A Machine Learning Prediction Model for Cardiac Amyloidosis Using Routine Blood Tests in Patients With Left Ventricular Hypertrophy

    Pan Y, Fan Q, Liang Y, Liu Y, You H, Liang C. A Machine Learning Prediction Model for Cardiac Amyloidosis Using Routine Blood Tests in Patients With Left Ventricular Hypertrophy. Scientific Reports. 2024;14:28644. https://doi.org/10.1038/s41598-024-77466-8

    2024 doi

  28. [36]

    Artificial Intelligence-Enabled Electrocardiography and Echocardiography to Track Preclinical Progression of Transthyretin Amyloid Cardiomyopathy

    Oikonomou EK, Sangha V, Shankar SV, Coppi A, Krumholz HM, Nasir K, et al. Artificial Intelligence-Enabled Electrocardiography and Echocardiography to Track Preclinical Progression of Transthyretin Amyloid Cardiomyopathy. European Heart Journal. 2025;46:3651–

    2025

  29. [37]

    https://doi.org/10.1093/eurheartj/ehaf450

    doi

  30. [38]

    How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges

    Kamel MA, Abbas MT, Kanaan CN, Awad KA, Ali NB, Scalia IG, et al. How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges. Journal of Cardiovascular Development and Disease. 2024;11:118. https://doi.org/10.3390/j...

    2024 doi

  31. [39]

    Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review

    Grogan M, Lopez‐Jimenez F, Guthrie S, Kumar N, Langevin R, Lousada I, et al. Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review. JAHA. 2025;14:e036533. https://doi.org/10.1161/JAHA....

    2025 doi

  32. [40]

    The Role of Artificial Intelligence in Cardiac Amyloidosis: A Focus on Diagnosis and Clinical Application

    Wardak R, Snipelisky D. The Role of Artificial Intelligence in Cardiac Amyloidosis: A Focus on Diagnosis and Clinical Application. Journal of Cardiovascular Development and Disease. 2025;12:221. https://doi.org/10.3390/jcdd12060221

    2025 doi

  33. [41]

    Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis

    Gill SS, Fellin E, Stampke L, Zhao Y, Masri A. Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis. Methodist DeBakey Cardiovascular Journal. 2022;18:36–46. https://doi.org/10.14797/mdcvj.1061

    2022 doi

  34. [42]

    Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis

    Vrudhula A, Stern L, Cheng PC, Ricchiuto P, Daluwatte C, Witteles R, et al. Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis. JACC: Advances. 2024;3:100998. https://doi.org/10.1016/j.jacadv.2024.100998

    2024 doi

  35. [43]

    Cardiac Amyloidosis Detection From a Single Echocardiographic Video Clip: A Novel Artificial Intelligence-Based Screening Tool

    Slivnick JA, Hawkes W, Oliveira J, Woodward G, Akerman A, Gomez A, et al. Cardiac Amyloidosis Detection From a Single Echocardiographic Video Clip: A Novel Artificial Intelligence-Based Screening Tool. European Heart Journal. 2025;46:ehaf387. https://doi.org/10.1093/eurheartj/ehaf387

    2025 doi

  36. [44]

    Cardiovascular Magnetic Resonance in Cardiac Amyloidosis

    Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2005;111:186–93. https://doi.org/10.1161/01.CIR.0000152819.97857.9D

    2005 doi

  37. [45]

    Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review

    Maggialetti N, Torrente A, Lorusso G, Villanova I, Ficco M, Gravina M, et al. Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review. Journal of Personalized Medicine. 2024;14:407. https://doi.org/10.3390/jpm14040407

    2024 doi

  38. [46]

    Deep Learning to Diagnose Cardiac Amyloidosis From Cardiovascular Magnetic Resonance

    Martini N, Aimo A, Barison A, Della Latta D, Vergaro G, Aquaro GD, et al. Deep Learning to Diagnose Cardiac Amyloidosis From Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance. 2020;22:84. https://doi.org/10.1186/s12968-020-00690-4

    2020 doi

  39. [47]

    Differentiating Between Cardiac Amyloidosis and Hypertrophic Cardiomyopathy on Non-Contrast Cine-Magnetic Resonance Images Using Machine Learning-Based Radiomics

    Jiang S, Zhang L, Wang J, Li X, Hu S, Fu Y, et al. Differentiating Between Cardiac Amyloidosis and Hypertrophic Cardiomyopathy on Non-Contrast Cine-Magnetic Resonance Images Using Machine Learning-Based Radiomics. Frontiers in Cardiovascular Medicine. 2022;9:1001269. https://d...

    2022 doi

  40. [48]

    Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations

    Schockling EJ, Farrell MB, Embry-Dierson M, Warren J, Jerome S. Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations. Journal of Nuclear Medicine Technology. 2023;51:90–8. https://doi.org/10.2967/jnmt.123.265416

    2023 doi

  41. [49]

    Reliability and feasibility of visual grading systems and quantitative indexes on [99mTc]Tc-DPD imaging for cardiac amyloidosis

    Bae S, Gil J, Paeng JC, Park E-A, Lee S-P, Choi H, et al. Reliability and feasibility of visual grading systems and quantitative indexes on [99mTc]Tc-DPD imaging for cardiac amyloidosis. Scientific Reports. Nature Publishing Group; 2022;12:17271. https://doi.org/10.1038/s41598...

    2022 doi

  42. [50]

    Quantitative 99mTc-DPD SPECT/CT in Patients With Suspected ATTR Cardiac Amyloidosis: Feasibility and Correlation With Visual Scores

    Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative 99mTc-DPD SPECT/CT in Patients With Suspected ATTR Cardiac Amyloidosis: Feasibility and Correlation With Visual Scores. Journal of Nuclear Cardiology. 2019;27:1456–63. https://doi.org/10.1007/s12350-019- 01893-8

    2019 doi

  43. [51]

    Transforming ATTR Cardiac Amyloidosis Into a Chronic Disease: The Enormous Potential of Quantitative SPECT to Improve Diagnosis, Prognosis, and Monitoring of Disease Progression

    Ayers MP, Peruri AV, Bourque JM. Transforming ATTR Cardiac Amyloidosis Into a Chronic Disease: The Enormous Potential of Quantitative SPECT to Improve Diagnosis, Prognosis, and Monitoring of Disease Progression. Journal of Nuclear Cardiology. 2021;28:1846–50. https://doi.org/1...

    2021 doi

  44. [52]

    Volumetric Evaluation of 99mTc-Pyrophosphate SPECT/CT for Transthyretin Cardiac Amyloidosis: Methodology and Correlation With Cardiac Functional Parameters

    Watanabe S, Nakajima K, Wakabayashi H, Yoneyama H, Yoshida S, Komatsu J, et al. Volumetric Evaluation of 99mTc-Pyrophosphate SPECT/CT for Transthyretin Cardiac Amyloidosis: Methodology and Correlation With Cardiac Functional Parameters. Journal of Nuclear Cardiology. 2021;29:3...

    2021 doi

  45. [53]

    Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform

    González-López E, Abbou R, López-García R, Brandão M, Perard L, Mora-Ayestaran N, et al. Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform. Heart Rhythm [Internet]. 2026 [cited 2026 May 30]; https:...

    2026 doi

  46. [54]

    Detection of cardiac amyloidosis using machine learning on routine echocardiographic measurements

    Chang RS-W, Chiu I, Tacon P, Abiragi M, Cao L, Hong G, et al. Detection of cardiac amyloidosis using machine learning on routine echocardiographic measurements. Open Heart. 2024;11:e002884. https://doi.org/10.1136/openhrt-2024-002884

    2024 doi

  47. [55]

    Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of- Concept Study

    Agibetov A, Seirer B, Dachs T-M, Koschutnik M, Dalos D, Rettl R, et al. Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of- Concept Study. JCM. 2020;9:1334. https://doi.org/10.3390/jcm9051334

    2020 doi

  48. [56]

    A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy

    Huda A, Castaño A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. 2021;12:2725. https://doi.org/10.1038/s41467-021-22876-9

    2021 doi

  49. [57]

    Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF

    Peters AE, Solomon N, Chiswell K, Fonarow GC, Khouri MG, Baylor L, et al. Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF. American Heart Journal. 2...

    2023 doi

  50. [58]

    Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center

    Mitchell JD, Lenihan DJ, Reed C, Huda A, Nolen K, Bruno M, et al. Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center. Clin Med Insights Cardiol. 2022;16:11795468221133608. https://doi.org/10...

    2022 doi

  51. [59]

    Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial

    Jain SS, Sun T, Pierson E, Roedan Oliver F, Malta P, Castillo M, et al. Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026;11:117. https://doi.org/10.1001/jamacardio.2025.4591

    2026 doi

  52. [60]

    UCSF. UCSF Cardiomyopathy Trial: Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Ran...

    2025

  53. [61]

    Salimi Y, Shiri I, Mansouri Z, Sanaat A, Hajianfar G, Hervier E, et al. Artificial intelligence- based cardiac transthyretin amyloidosis detection and scoring in scintigraphy imaging: multi- tracer, multi-scanner, and multi-center development and evaluation study. Eur J Nucl M...

    2025 doi

  54. [62]

    Stacking Ensemble Learning-Based Models Enabling Accurate Diagnosis of Cardiac Amyloidosis Using SPECT/CT: An International and Multicentre Study

    Mo Q, Cui J, Jia S, Zhang Y, Xiao Y, Liu C, et al. Stacking Ensemble Learning-Based Models Enabling Accurate Diagnosis of Cardiac Amyloidosis Using SPECT/CT: An International and Multicentre Study. medRxiv. 2025; https://doi.org/10.1101/2025.06.22.25330039

    2025 doi

  55. [63]

    Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

    Agibetov A, Kammerlander A, Duca F, Nitsche C, Koschutnik M, Donà C, et al. Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging. JPM. 2021;11:1268. https://doi.org/10.3390/jpm11121268

    2021 doi

  56. [64]

    Diagnosis of Cardiac Amyloidosis Using a Radiomics Approach Applied to Late Gadolinium-Enhanced Cardiac Magnetic Resonance Images: A Retrospective, Multicohort, Diagnostic Study

    Zhou XY, Tang CX, Guo YK, Tao XW, Chen WC, Guo JZ, et al. Diagnosis of Cardiac Amyloidosis Using a Radiomics Approach Applied to Late Gadolinium-Enhanced Cardiac Magnetic Resonance Images: A Retrospective, Multicohort, Diagnostic Study. Front Cardiovasc Med. 2022;9:818957. htt...

    2022 doi

  57. [65]

    Development and validation of a radiomics model for detecting cardiac amyloidosis at coronary computed tomography angiography

    Meng Q, Zhao L, Sun X, Wang Y, Yu L, Schoepf UJ, et al. Development and validation of a radiomics model for detecting cardiac amyloidosis at coronary computed tomography angiography. European Heart Journal - Cardiovascular Imaging. 2025;26:1039–48. https://doi.org/10.1093/ehjc...

    2025 doi

  58. [66]

    Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

    Shiri I, Balzer S, Baj G, Bernhard B, Hundertmark M, Bakula A, et al. Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis. Eur J Nucl Med Mol Imaging. 2025;52:485–500. https://doi.org/10.1007/s0025...

    2025 doi

  59. [67]

    Artificial intelligence– driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes

    Miller RJh, Shanbhag A, Shahi K, Bosley D, Litwin L, White JA, et al. Artificial intelligence– driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes. Journal of Nuclear Cardiology. 2026...

    2026 doi

  60. [68]

    Artificial Intelligence- Based Echocardiographic Assessment for Monitoring Disease Progression in Transthyretin Cardiac Amyloidosis

    Venneri L, Aimo A, Porcari A, Sezer I, Ioannou A, Sheikh A, et al. Artificial Intelligence- Based Echocardiographic Assessment for Monitoring Disease Progression in Transthyretin Cardiac Amyloidosis. European Journal of Heart Failure. 2025;27:3392–400. https://doi.org/10.1002/...

    2025 doi

  61. [69]

    Predictors of Mortality by an Artificial Intelligence Enhanced Electrocardiogram Model for Cardiac Amyloidosis

    Amadio JM, Grogan M, Muchtar E, Lopez-Jimenez F, Attia ZI, AbouEzzeddine O, et al. Predictors of Mortality by an Artificial Intelligence Enhanced Electrocardiogram Model for Cardiac Amyloidosis. ESC Heart Failure. 2025;12:677–82. https://doi.org/10.1002/ehf2.15061

    2025 doi

  62. [70]

    Predicting Prognosis of Light-Chain Cardiac Amyloidosis by Magnetic Resonance Imaging and Deep Learning

    Wang S, Liu C, Guo Y, Sang H, Li X, Lin L, et al. Predicting Prognosis of Light-Chain Cardiac Amyloidosis by Magnetic Resonance Imaging and Deep Learning. European Heart Journal – Cardiovascular Imaging. 2025;26:1771–81. https://doi.org/10.1093/ehjci/jeaf248

    2025 doi

  63. [71]

    Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

    Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. JCO. 2004;22:3751–7. https://doi.org/10.1200/JCO.2004.03.029

    2004 doi

  64. [72]

    Late gadolinium enhanced cardiac MR derived radiomics approach for predicting all-cause mortality in cardiac amyloidosis: a multicenter study

    Zhou XY, Tang CX, Guo YK, Chen WC, Guo JZ, Ren GS, et al. Late gadolinium enhanced cardiac MR derived radiomics approach for predicting all-cause mortality in cardiac amyloidosis: a multicenter study. Eur Radiol. 2023;34:402–10. https://doi.org/10.1007/s00330-023-09999-x

    2023 doi

  65. [73]

    Artificial Intelligence-Enhanced Electrocardiogram: A Possible Mechanism to Monitor Cardiac Amyloidosis Therapeutic Response

    Schlesinger RP, Ferreira Felix I, Harmon DM, Malik AA, Dispenzieri A, Fonseca R, et al. Artificial Intelligence-Enhanced Electrocardiogram: A Possible Mechanism to Monitor Cardiac Amyloidosis Therapeutic Response. JACC: Case Reports. 2025;30:102968. https://doi.org/10.1016/j.j...

    2025 doi

  66. [74]

    TRIPOD+AI Statement: Updated Guidance for Reporting Clinical Prediction Models That Use Regression or Machine Learning Methods

    Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI Statement: Updated Guidance for Reporting Clinical Prediction Models That Use Regression or Machine Learning Methods. BMJ. 2024;385:e078378. https://doi.org/10.1136/bmj-2023-078378

    2024 doi

  67. [75]

    Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update

    Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, et al. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update. Radiology: Artificial Intelligence. 2024;6:e240300. https://doi.org/10.1148/ryai.240300

    2024 doi

  68. [76]

    Analysis of FDA- Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices

    Sardar P, Dudorova E, Chatterjee S, Parikh SA, Brilakis ES, Singh JP. Analysis of FDA- Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices. JACC: Advances. 2025;4:102174. https://doi.org/10.1016/j.jacadv.2025.102174

    2025 doi

  69. [77]

    FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare

    Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025;388:e081554. https://doi.org/10.1136/bmj-2024-081554

    2025 doi

  70. [78]

    A new staging system for cardiac transthyretin amyloidosis

    Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal. 2018;39:2799–806. https://doi.org/10.1093/eurheartj/ehx589

    2018 doi

  71. [79]

    PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods

    Moons KGM, Damen JAA, Kaul T, Hooft L, Andaur Navarro C, Dhiman P, et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505. https://doi.org/10.1136/b...

    2025 doi

  72. [80]

    Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI

    Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med. 2022;28:924–33. https://doi.org/10.1038/s41591-022-01772- 9

    2022 doi

  73. [81]

    AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy [Internet]

    Germans Trias i Pujol Hospital. AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy [Internet]. clinicaltrials.gov; 2026 Apr. Report No.: NCT07529860. https://clinicaltrials.gov/...

    2026

  74. [82]

    Machine learning studies in cardiac amyloidosis, organized by clinical task A. Screening and risk enrichment studies in cardiac amyloidosis Study Modality / input Cohort / design Model / approach Main reported result Validation level Target / label Contribution Schrutka et al....

    2021

  75. [83]

    Feature representations used in cardiac amyloidosis AI studies and their clinical interpretation Feature group Specific features used Modality / task Clinical interpretation Main impact Latent deep learning features Learned ECG, echo -video, CMR, and scintigraphy representatio...

Pith tools

Reviewed July 14, 2026 · model on record in the stance chip above.